JEREMY V. COOKE, M.D.; PAUL V. HOLLAND, M.D.; N. RAPHAEL SHULMAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Pool's original method of preparing cryoprecipitate for treating hemophilia was found to be suitable for preparing factor VIII from acidified plasma that is a by-product of platelet concentrates. Preparation of cryoprecipitate was simplified by using residual ice crystals as a collecting filter to eliminate centrifugation and as a suspending medium to eliminate exogenous diluent. Experience with four hemophiliacs undergoing seven surgical procedures is described. Satisfactory factor VIII levels were easily maintained with cryoprecipitate in all patients, and no complications were associated with its use. Recovery of factor VIII in vitro and in vivo is evaluated, and therapeutic regimens that allow for variations in yield to assure hemostasis without laboratory control are outlined. Cryoprecipitate is superior to plasma and as effective as commercially available factor VIII concentrates but cheaper.
COOKE JV, HOLLAND PV, SHULMAN NR. Cryoprecipitate Concentrates of Factor VIII for Surgery in Hemophiliacs. Ann Intern Med. ;68:39–47. doi: 10.7326/0003-4819-68-1-39
Download citation file:
Published: Ann Intern Med. 1968;68(1):39-47.
Coagulopathies, Endocrine and Metabolism, Hematology/Oncology, Hospital Medicine, Rheumatology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use